(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -34.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.88%.
Entrada Therapeutics's revenue in 2025 is $210,782,000.On average, 4 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,498,333,979, with the lowest TRDA revenue forecast at $751,892,600, and the highest TRDA revenue forecast at $2,121,089,025. On average, 1 Wall Street analysts forecast TRDA's revenue for 2026 to be $2,121,089,025, with the lowest TRDA revenue forecast at $2,121,089,025, and the highest TRDA revenue forecast at $2,121,089,025.
In 2027, TRDA is forecast to generate $2,121,089,025 in revenue, with the lowest revenue forecast at $2,121,089,025 and the highest revenue forecast at $2,121,089,025.